MedTrace Logo

A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease

NCT04102111 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-02-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy of JNJ-active as measured by the change in the Crohn's Disease Activity Index (CDAI) score and Simplified Endoscopic Score for Crohn's disease (SES-CD) from baseline at Week 12.

Conditions

  • Crohn Disease

Interventions

DRUG

JNJ-67864238

Participants will receive oral tablets of JNJ-67864238 twice daily.

DRUG

Placebo

Participants will receive oral tablets of matching placebo twice daily.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-23
Primary Completion
2021-11-17
Completion
2021-12-22
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Germany
  • Italy
  • Poland
  • Russia
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04102111 on ClinicalTrials.gov